However, we found that most acute myeloid leukemia (AML) cells, especially M4 and M5 subtypes, produce TNF and show basal level activation of RIP1/RIP3/MLKL signaling, yet do not undergo necroptosis.

However, it has proven difficult to identify such specific antigens in certain cancer types, including acute myeloid leukemia (AML). AML patients are often treated using allogeneic hematopoietic ...

granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia (AML). AB8939 had already obtained orphan drug designation from the US Food and Drug Administration (FDA ...